On December 29, 2011, Deng, Yongqi; Zhu, Liang; Shipps, Gerald W., Jr.; Lo, Sie-Mun; Sun, Binyuan; Huang, Xiaohua; Beinstock, Corey; Cooper, Alan B.; Gao, Xiaolei; Yao, Xin; Zhu, Hugh Y.; Kelly, Joseph M.; Boga, Sobhana Babu; Alhassan, Abdul-Basit; Tagat, Jayaram R.; Mansoor, Umar Faruk; Wilson, Kevin; O’Boyle, Brendan M.; Daniels, Matthew; Schell, Adam; Siliphaivanh, Phieng; Fischer, Christian published a patent.Application of 872046-08-7 The title of the patent was Indazolecarboxamide derivatives as ERK inhibitors and their preparation and use for the treatment of cancer. And the patent contained the following:
The invention relates to indazolecarboxamide derivatives of formula I, which are ERK inhibitors and which are useful in the treatment of cancer. Compounds of formula I wherein R is H, alkyl and hydroxyalkyl; R1 is (un)substituted heterocyclyl, (un)substituted heterocycloalkenyl, (un)substituted aryl and (un)substituted heteroaryl; R2 is H and alkyl; R3′ is (un)substituted piperidinyl, (un)substituted azepanyl, (un)substituted oxazepanyl, etc.; and pharmaceutically acceptable salts, solvates and esters thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their ERK inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values of 14.4 nM and 28.1 nM towards cERK and aERK, resp. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Application of 872046-08-7
The Article related to indazolecarboxamide preparation erk inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application of 872046-08-7
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics